If you were using it specifically for something your doctor recommended through a compounding pharmacy, thats a very different situation than if you were self-injecting something you ordered from a peptide supplier in a foreign country
Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure
At 1.0mg doses, you are drawing 0.60 mL per week, which significantly reduces the number of doses per vial
Semaglutide works by slowing stomach emptying and signaling fullness to the brain, but this mechanism becomes unpredictable and risky at double the prescribed dose
That is a real rationale and it is also why the short-acting No-DAC form, not the DAC version whose data everyone quotes, is the one that belongs in the pairing
Endocrinology 155, 12801290 (2014)